← All Dossiers
WovenX Health – Seed
Offered To Invest Seed · $800K new Fund II check · $16M pre / $21M post · Co-lead with Corazon Capital
Dossier generated 2026-07-08 by /deal-dossier  ·  Deal record: recdCUsZnHSQ6axFh  ·  Source: Airtable appjxAR3LPe3fkHOp

One-Liner & Thesis

WovenX (formerly Telebelly Health) is a Chicago-based, AI-enabled specialty-care platform that pairs virtual, GI-trained Advanced Practice Providers with in-network brick-and-mortar practices to compress specialty appointment wait times from ~60 days to ~11 minutes and procedure wait times from ~10 weeks to ~2 weeks. The company has served 140,000+ patients in its beachhead specialty (gastroenterology), closed enterprise agreements with GI Alliance, Gastro Health, Idaho GI, and Washington Gastroenterology, and just finalized a pilot with Exact Sciences that carries $250–$330K near-term and up to $15M in annual expansion value.

Thesis: WovenX is a rare digital-health seed earning real GAAP revenue ($2.3M 2025, $4M CARR, $6M 2026 target) in a $400B+ specialty access market that health systems and payers are actively trying to fix — and StoryHouse can co-lead a priced Series Seed at $16M pre alongside Corazon Capital, taking meaningful Fund II ownership behind a management team that previously helped build and sell MDLIVE. The drag on conviction is a bruising four-month fundraise: despite a term sheet in hand and audited traction, the company could not attract a healthcare-focused institutional check and had to defend $16M pre against a $12M pre insider fallback, which signals downstream Series A pricing risk and softer market validation than the operating metrics suggest.

Investment Score & Recommendation

72
/ 100
INVEST
Biggest driver: real, priced, GAAP-recognized revenue growing 2.5–3x YoY in a large specialty-access TAM with blue-chip logos (GI Alliance, Gastro Health, Washington GI, Exact Sciences). Biggest drag: the round could not attract a new healthcare-institutional lead in four months of process — Fund II gets attractive terms only because the syndicate stayed insider-heavy, and the same softness is likely to reappear at Series A.
Momentum: Steady Red flags: 3 Confidence: MEDIUM
Market & TAM8/10
Weight 25%
Team & Founder8/10
Weight 25%
Product & Traction8/10
Weight 20%
Deal Terms & Return6/10
Weight 20%
VC Syndicate5/10
Weight 10%

Deal Box

Round Size
$5.0M target ($4.25M minimum)
Valuation / Cap
$16M pre-money / $21M post-money · $0.6476 / share
Lead Investor
StoryHouse Ventures & Corazon Capital (co-lead)
Co-Investors
Hyde Park Angels, DePaul University, South Dakota First Capital, Health Tech Capital
SH Check
$800,000 (Fund II new) + $100K Fund I SAFE converting to 283,607 shares
Fund
StoryHouse Fund II
Funding Round
Series Seed (priced equity)
Vehicle
Series Seed Preferred · Corazon $1.7M / SH $800K / HPA ~$530K / DePaul $150K / SDFC $750K / Health Tech Cap $300–500K

Company Snapshot

Sector
Healthcare · Information Technology · Personal Health
Location
Chicago, Illinois
Headcount
Small operating team plus contracted APP network
Founded
2021-08-01
Total Raised (pre-round)
~$3.2M in SAFEs (last cap $8M)
Website
wovenxhealth.com
Status
Private · Active
Prior Name
Telebelly Health (rebranded 2025)

Market Size (TAM)

$400B+
US Specialty Care SpendInternal
Company-cited addressable spend across specialty care access
$9.8B
GI Telehealth 2024Web
Global gastroenterology telehealth market (Grand View, 2024)
24.6%
GI Telehealth CAGRWeb
Forecast CAGR 2024–2030 (Grand View Research)
$219B
Global Telehealth 2026Web
Fortune Business Insights, global telehealth market
50%
US ZIPs w/in 30mi of PartnerInternal
Network reach via GI Alliance / Gastro Health / Washington GI

The specialty-access wedge is real: US gastroenterology has the longest specialist wait times of any surgical specialty and accounts for a disproportionate share of avoidable ED utilization. The company’s $400B+ framing is the full specialty-care spend; the immediately serviceable slice (GI virtual-care software plus APP staffing to health-system partners) is materially smaller but is compounding above 20% annually and sits inside a global telehealth market growing from $186B (2025) to $219B (2026) Web. TAM alone is not the constraint here — the constraint is enterprise sales cycles into large GI groups and health systems.

Competition

CompanyPositioningTraction / NoteSource
WovenX HealthVirtual-first GI specialty platform & APP network integrated with brick-and-mortar practices; agentic AI supervision (100% chart review, 15 functional agents)140K+ patients, $4M CARR, 11-min access, 80+ NPSInternal
GI Alliance in-house digitalLargest US GI roll-up’s internal digital access & scheduling stack (Cardinal Health acquired GI Alliance in 2025)WovenX is a paid partner, not a competitor; roll-up scale creates distribution risk if in-house build acceleratesWeb
Oshi HealthVirtual GI clinic, direct-to-employer / payer distributionPeterson Health Institute validated real savings ~$2.5K/patient vs. claimed $10K across GI digital cohortWeb
Vivante Health (GIThrive)Digital GI benefit for self-insured employersPayer/employer channel; different buyer than WovenX’s health-system focusWeb
Cylinder / K Health GIConsumer-facing digestive-health apps & asynchronous virtual careConsumer-first; do not deliver procedural throughput to ASCsWeb
MDLIVE / Teladoc specialtyBroad multi-specialty telehealthWovenX CTO / product team previously scaled MDLIVE (acquired by Cigna) — same playbook, GI-specializedInternal

Moat: WovenX is the only asset positioned squarely at the health-system / practice buyer with a hybrid model that both routes patients and unlocks procedural throughput inside partner ASCs — its distribution partnerships with the three largest US GI groups create a two-sided data set (4K+ recorded hours, 8M+ data points) that pure D2C or employer-benefit competitors cannot replicate, and Peterson Institute’s validation of the broader cohort’s claims (~$2.5K real savings vs. $10K claimed) advantages the operator that partners with, rather than disintermediates, existing practices.

Traction Metrics

$2.3M
2025 GAAP RevenueInternal
Actuals, per Feb 2026 diligence call
$4.0M
Current CARRInternal
$2.5M ARR run-rate plus $1.2M Q1 2026 signings
$6.0M
2026 GAAP TargetInternal
At ~53% gross margin
45–50%
Gross MarginInternal
Guided path to 70% by 2028
140K+
Patients ServedInternal
First specialty (GI)
11 min
Access WaitInternal
Down from 60+ days
80+
Patient NPSInternal
vs. ~30 healthcare avg
<1%
ED EscalationInternal
Down from 41% pre-visit intent
24 mo
Expected RunwayInternal
Post-close of Series Seed

Enterprise contracts progressing in parallel: Exact Sciences pilot finalized May 2026 ($250–$330K near-term, up to $15M expansion); Gastro Health two-pilot deployment kicked off in Washington state; second GI Alliance site went live in Mississippi; 80+ care navigators trained on Idaho GI OnDemand with volume up 150% in the first week. Washington Gastroenterology publicly reported a 72% reduction in time-to-procedure and $5.4M in new revenue attributable to the WovenX partnership Web. In June 2025, CRH Medical (a WELL Health subsidiary) announced a strategic partnership with WovenX to advance GI patient access — the kind of channel that meaningfully accelerates distribution into ASCs Web.

Exit Potential

Strategic M&A
Likely PathInternal
5–7 yrs
Time to LiquidityInternal
6–10x
Fund II Return CaseInternal
On $800K at $21M post
277
H1’25 HealthTech M&AWeb
On pace to exceed 2024’s 467 deals (Corum / STAT)

Most probable exit is strategic acquisition by a specialty-care roll-up (GI Alliance / Cardinal Health, US Digestive Health), a diagnostics-plus-services platform (Exact Sciences was flagged as a partner-turned-acquirer path before Abbott announced its ~$21B acquisition of Exact Sciences in Nov 2025 Web), a payer-owned services arm (Optum, Elevance/Carelon), or a large virtual-care platform seeking a GI beachhead (Teladoc, Included Health, WELL Health — the latter already partnered via CRH Medical in June 2025 Web). Digital-health M&A activity re-accelerated meaningfully in 2025 with 277 deals in H1 alone and $10.3B in disclosed value, and PE-backed GI roll-ups continue to consolidate at pace, both of which create multiple credible bidders for a scaled, GI-specialized asset over a 5–7 year horizon Web.

Founders

Sheri Rudberg
Co-Founder & CEO
20+ years in health tech across strategy, legal, M&A, business development, and operations. Previously scaled medical-services businesses; drives commercial execution, syndicate management, and enterprise sales. University of Illinois at Urbana-Champaign. Family of three kids and two dogs.
Russ Arjal, MD
Co-Founder & Chief Medical Officer
Practicing gastroenterologist; previously helped lead a national GI practice; member of the AGA governing board and nationally recognized GI thought leader. Focus is on increasing patient access via tech-enablement and driving medical credibility with practice partners. Deferential to Sheri on operations; team chemistry described in diligence as respectful with differences of opinion resolved well. Played tennis at Pomona.
CTO & Core Product Team
MDLIVE Alumni
CTO and core product team previously built and scaled MDLIVE, a broad-based telehealth platform acquired by Cigna. Directly relevant playbook for scaling a multi-tenant clinical-operations platform into health-system and payer distribution.

Open Questions & Risks

Next Steps

Latest Meeting Notes

2026-07-06 Deal Call Major-investor rights & docs — Corazon alignment
Corazon called to align on an open item in closing docs: whether StoryHouse and Corazon are explicitly named as “major investors.” Company counsel is pushing back, calling it “out of market.” Both firms already qualify above the $900K threshold, so the naming is a preference, not a necessity. Rights (info + pro rata) exist regardless between now and next round, and a new lead at Series A will likely remove the designation anyway.
Contact: Sheri Rudberg · Notes: Deal call, 2026-07-06
2026-07-02 Corazon Sync Round tracking to $16M pre at ~$3.93M
Josh (Corazon) and StoryHouse aligned that the round is likely to close on original $16M pre terms if South Dakota First Capital ($750K committed) and Health Tech Capital ($300–500K, confirming Monday) both stick. HPA at $530K. Sheri wants to close by Jul 10 before a two-week Africa trip; both firms agree that is not realistic given legal pause, holiday weekend, and outstanding confirmatory diligence.
Contact: Josh Graves (Corazon) · Notes: Corazon sync, 2026-07-02
2026-06-25 Reference Call SDFC late-stage diligence — Matthew as reference for Sheri & Russ
Reference call for South Dakota First Capital (SDFC), an $18M generalist fund based in the Midwest with a regional-hospital LP and health-tech thesis. StoryHouse endorsed Sheri and Russ as experienced operators with complementary skills; called out Exact Sciences as a flywheel catalyst; flagged multi-vertical temptation as the top execution risk. SDFC is in late-stage diligence and needs to move inside two weeks to participate.
Contact: Sheri Rudberg & Russ Arjal · Notes: Reference call for SDFC, 2026-06-25

Deal Timeline

Reference Calls

2026-06-25 Reference — SDFC Matthew as reference for Sheri Rudberg & Russ Arjal
South Dakota First Capital ($18M generalist fund, 18 months into deployment, regional-hospital lead LP) asked StoryHouse for a reference on the WovenX founders as part of late-stage diligence. Matthew described Sheri as an experienced executive who has scaled medical-services businesses and Russ as the medical-credibility engine who defers to Sheri on operations; team chemistry described as respectful, differences of opinion resolved well. Key risk raised: the temptation to launch multiple verticals too early — Matthew’s strong preference is that WovenX go deep in GI, solidify SOPs and team, and only then expand.
Referenced founders: Sheri Rudberg, Russ Arjal — SDFC (Mark Towers, Lucas Haskins) — 2026-06-25